QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
QQQ   294.62 (+1.50%)
AAPL   144.29 (+0.90%)
MSFT   247.81 (+2.10%)
META   148.97 (+1.30%)
GOOGL   98.84 (+1.96%)
AMZN   103.13 (+2.57%)
TSLA   173.22 (+3.94%)
NVDA   195.37 (+1.96%)
NIO   12.07 (+0.42%)
BABA   110.20 (-0.90%)
AMD   75.15 (+3.73%)
T   20.37 (+1.04%)
MU   60.30 (-2.28%)
F   13.51 (+4.81%)
CGC   3.03 (+6.69%)
GE   80.48 (-0.43%)
DIS   108.49 (+0.84%)
AMC   5.35 (+6.79%)
PFE   44.16 (+1.40%)
PYPL   81.49 (+2.32%)
NFLX   353.86 (+0.21%)
NYSE:SQZ

SQZ Biotechnologies - SQZ Stock Forecast, Price & News

$0.82
-0.01 (-1.20%)
(As of 01/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.79
▼
$0.86
50-Day Range
$0.67
▼
$2.65
52-Week Range
$0.65
▼
$8.21
Volume
112,771 shs
Average Volume
162,318 shs
Market Capitalization
$24.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.75

SQZ Biotechnologies MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
845.1% Upside
$7.75 Price Target
Short Interest
Healthy
1.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.50) to ($1.93) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

773rd out of 1,055 stocks

Biological Products, Except Diagnostic Industry

123rd out of 170 stocks

See Top Rated MarketRank™ Stocks Here

SQZ stock logo

About SQZ Biotechnologies (NYSE:SQZ) Stock

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, autoimmune, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with other immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. SQZ Biotechnologies Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Receive SQZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SQZ Stock News Headlines

January 19, 2023 | msn.com
SQZ Biotechnologies gets non-compliance notice from NYSE
January 18, 2023 | finance.yahoo.com
SQZ Biotechnologies Receives Notice Regarding Continued Listing Standards From the New York Stock Exchange
January 31, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 16, 2022 | benzinga.com
SQZ Biotechnologies's Return On Capital Employed Overview
December 6, 2022 | finance.yahoo.com
SQZ Biotechnologies Receives FDA Fast Track Designation for its eAPC Therapeutic Candidate for Treatment of HPV16+ Tumors and Presents Clinical Data for Multiple Programs at the European Society for Medical Oncology Immuno-Oncology Congress
December 1, 2022 | benzinga.com
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SQZ Biotechnologies Company - SQZ
December 1, 2022 | markets.businessinsider.com
Analyst Ratings for SQZ Biotechnologies
December 1, 2022 | markets.businessinsider.com
Expert Ratings for SQZ Biotechnologies
January 31, 2023 | Porter & Company (Ad)
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
December 1, 2022 | seekingalpha.com
SQZ Biotech CEO steps down amid 60% workforce reduction, pause on some clinical programs
December 1, 2022 | finance.yahoo.com
Roche-partnered cell therapy company lays off most of its staff, loses CEO, CFO
November 30, 2022 | finance.yahoo.com
SQZ Biotechnologies Announces Strategic Prioritization of SQZ® Enhanced Antigen Presenting Cells Program; Armon Sharei to Step Down as Chief Executive Officer
November 12, 2022 | finance.yahoo.com
SQZ Biotechnologies Third Quarter 2022 Earnings: EPS Beats Expectations, Revenues Lag
November 10, 2022 | finance.yahoo.com
SQZ Biotechnologies Presents Cell Squeeze® Manufacturing Platform, Linked Antigen mRNA Preclinical Research, and COMMANDER-001 Phase 1/2 Clinical Trial in Progress Poster at Society for Immunotherapy of Cancer Annual Meeting
November 9, 2022 | finance.yahoo.com
SQZ Biotechnologies Reports Third Quarter 2022 Financial Results and Recent Portfolio Updates
November 8, 2022 | finance.yahoo.com
Multiple insiders bought SQZ Biotechnologies Company (NYSE:SQZ) stock earlier this year, a positive sign for shareholders
October 3, 2022 | benzinga.com
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform's Potential as an Effective Red Blood Cell-Derived Immunotherapy
October 3, 2022 | finance.yahoo.com
SQZ Biotechnologies Publishes Preclinical Research Demonstrating SQZ® AAC Platform’s Potential as an Effective Red Blood Cell-Derived Immunotherapy
September 26, 2022 | nasdaq.com
Is SQZ Biotechnologies (NYSE:SQZ) In A Good Position To Invest In Growth?
September 12, 2022 | finance.yahoo.com
SQZ Biotechnologies Presents Preclinical SQZ® TIL Data Supporting Potential Ability of mRNA-Driven IL-2 and IL-12 Expression to Eliminate Need for Toxic Preconditioning and Systemic IL-2 Administration for Certain T Cell Therapies
September 6, 2022 | finance.yahoo.com
SQZ Biotechnologies Announces Leadership Transition
August 11, 2022 | finance.yahoo.com
Will SQZ Biotechnologies (NYSE:SQZ) Spend Its Cash Wisely?
August 4, 2022 | seekingalpha.com
SQZ Biotechnologies GAAP EPS of -$0.78 misses by $0.01, revenue of $3.22M misses by $0.97M
August 4, 2022 | finance.yahoo.com
SQZ Biotechnologies Reports Second Quarter 2022 Financial Results and Recent Portfolio Updates
July 30, 2022 | nasdaq.com
SQZ Biotechnologies (NYSE:SQZ) shareholders have endured a 78% loss from investing in the stock a year ago
July 12, 2022 | finance.yahoo.com
SQZ Biotechnologies and Collaborators Publish Technology Review on SQZ® APCs and Effective CD8 T Cell Activation
July 11, 2022 | finance.yahoo.com
SQZ Biotechnologies Appoints Micah Zajic as Chief Financial Officer
See More Headlines
Receive SQZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SQZ Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SQZ Company Calendar

Last Earnings
11/09/2022
Today
1/31/2023
Next Earnings (Estimated)
3/15/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSE:SQZ
CUSIP
N/A
CIK
1604477
Web
www.sqzbiotech.com
Phone
617-758-8672
Fax
N/A
Employees
113
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.75
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+845.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($2.71)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-68,740,000.00
Net Margins
-355.20%
Pretax Margin
-355.20%
Return on Equity
-80.63%
Return on Assets
-40.80%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.46
Quick Ratio
3.46

Sales & Book Value

Annual Sales
$27.10 million
Price / Sales
0.89
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$4.42 per share
Price / Book
0.19

Miscellaneous

Outstanding Shares
29,450,000
Free Float
23,944,000
Market Cap
$24.15 million
Optionable
Not Optionable
Beta
2.79

Key Executives

  • Dr. Howard Bernstein M.D. (Age 65)
    Ph.D., Interim CEO & Director
    Comp: $546.52k
  • Mr. Lawrence J. Knopf (Age 60)
    Gen. Counsel
    Comp: $478.04k
  • Dr. Robert S. Langer Jr. (Age 73)
    Ph.D., Sc.D., SCD, Co-Founder & Member of Scientific Advisory Board
  • Mr. Micah Zajic (Age 41)
    Chief Financial Officer
  • Mr. Richard V. Capasso CPA (Age 60)
    Chief Accounting Officer
  • Mr. David First (Age 58)
    Chief People Officer
  • Dr. Marshelle Smith Warren M.D.
    Chief Medical Officer
  • Ipsita Roymoulik Ph.D.
    Sr. VP of CMC & QUALITY

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













SQZ Stock - Frequently Asked Questions

Should I buy or sell SQZ Biotechnologies stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SQZ Biotechnologies in the last twelve months. There are currently 1 sell rating, 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" SQZ shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SQZ, but not buy additional shares or sell existing shares.
View SQZ analyst ratings or view top-rated stocks.

What is SQZ Biotechnologies' stock price forecast for 2023?

4 Wall Street analysts have issued 1-year target prices for SQZ Biotechnologies' stock. Their SQZ share price forecasts range from $2.00 to $15.00. On average, they anticipate the company's stock price to reach $7.75 in the next year. This suggests a possible upside of 850.9% from the stock's current price.
View analysts price targets for SQZ or view top-rated stocks among Wall Street analysts.

How have SQZ shares performed in 2023?

SQZ Biotechnologies' stock was trading at $0.74 on January 1st, 2023. Since then, SQZ shares have increased by 10.1% and is now trading at $0.8150.
View the best growth stocks for 2023 here.

When is SQZ Biotechnologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our SQZ earnings forecast.

How were SQZ Biotechnologies' earnings last quarter?

SQZ Biotechnologies (NYSE:SQZ) issued its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.77) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.12. The business had revenue of $3.45 million for the quarter, compared to the consensus estimate of $4.29 million. SQZ Biotechnologies had a negative trailing twelve-month return on equity of 80.63% and a negative net margin of 355.20%.

When did SQZ Biotechnologies IPO?

(SQZ) raised $75 million in an IPO on Friday, October 30th 2020. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Securities and Stifel acted as the underwriters for the IPO and BTIG was co-manager.

What is SQZ Biotechnologies' stock symbol?

SQZ Biotechnologies trades on the New York Stock Exchange (NYSE) under the ticker symbol "SQZ."

Who are SQZ Biotechnologies' major shareholders?

SQZ Biotechnologies' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Amy W Schulman, Klavs F Jensen and Richard Capasso.
View institutional ownership trends.

How do I buy shares of SQZ Biotechnologies?

Shares of SQZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SQZ Biotechnologies' stock price today?

One share of SQZ stock can currently be purchased for approximately $0.82.

How much money does SQZ Biotechnologies make?

SQZ Biotechnologies (NYSE:SQZ) has a market capitalization of $24.00 million and generates $27.10 million in revenue each year. The company earns $-68,740,000.00 in net income (profit) each year or ($2.71) on an earnings per share basis.

How many employees does SQZ Biotechnologies have?

The company employs 113 workers across the globe.

How can I contact SQZ Biotechnologies?

SQZ Biotechnologies' mailing address is 200 ARSENAL YARDS BLVD. STE. 210, WATERTOWN MA, 02472. The official website for the company is www.sqzbiotech.com. The company can be reached via phone at 617-758-8672 or via email at investors@sqzbiotech.com.

This page (NYSE:SQZ) was last updated on 1/31/2023 by MarketBeat.com Staff